Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Ingrid Goldberg

Good morning, everyone, and thank you for joining us to review Novocure's Fourth Quarter and Full Year 2022 Performance. I'm joined on the phone by our Executive Chairman, Bill Doyle; our CEO, Asaf Danziger; and our CFO, Ashley Cordova. Other members of our executive leadership team are also on the call and available for Q&A.

For your reference, slides accompanying this earnings release can be found on our website, www.Novocure.com, under Quarterly Reports on our Investor Relations page.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. filings. number our and from control time our a which some time involve in beyond are and SEC statements of uncertainties, risks of to These are described any We forward-looking law. do to not update statements, as required intend except by publicly

to and we and measures the financial of page press believe with on an also tax EBITDA today. These measures best share-based adjusted are compensation. non-cash Relations our earnings refer generated business, before interest, be important to items; financial of of the SEC is it impact a We earnings accessed measure Where our our in in reflects filed earnings our release, by removes metric Reconciliations our X-K can taxes, specifically business. capital non-GAAP and appropriate, rate Investor included GAAP evaluate our EBITDA, to depreciation, materials the as slides amortization value attributable adjusted our structure, to from non-GAAP website. and financial material Form

open remarks questions. Following our we your for the today, line prepared will

Executive will our call turn Bill Doyle. the over to now I Chairman,

William Doyle

cancer patient Thank can the treated to harnessed and electric novel that Novocure And fields morning, survival. treatment cancer and the XX,XXX cells built Since kill for founded XXXX, exploit incredible in business finding enhance to over expand Tumor product to extend Fields a good and commercial therapy you, the was invested resilient tumor Ingrid. XXXX be everyone. and capabilities patients, solid programs in extensive cancers. development clinical Treating of of we've

in Optune out our more we received to reimbursement to $XXX in material patients; made approval we our finalized contract national million revenue, pending successfully generation terms deliver thinner, in net are we and our in France, achieved arrays business, in and significant energy lighter, and In generated may publication; next final final which progress Novocure Austria, non-small XXXX, rolled and year; milestones. its Canada, pivotal endpoint; later In programs, for pivotal overall LUNAR survival and immune launched the in X-THE-TOP pilot establish in commercial clinical cell treating data the with study completing data temozolomide pilot plus inhibitor, primary with and met explored positive this lung TTFields the pembrolizumab. our GBM announcing INNOVATE-X analysis cancer announcing David checkpoint Dr. anticipated patients cancer study interim and INNOVATE-X study, Tran's gastric which and

we of our of week, pivotal study of Last just we of as morning, brain in pivotable patients enrollment from study from two lung completion enrollment cancer. non-small cell cancer. pancreatic METIS in this PANOVA-X completing metastases away announced And are our

of motivated company. XXXX solid all shape the was are a year future execution for excited teams our and in us XXXX. our awaits that that will And of

call a discussion We will with begin of GBM business. today's our

milestones. We near clinical will and pipeline our term then review

XXXX performance financial opening for review our the fourth quarter Finally, we of line questions. will before the in

Our treating growth. foundation solid provides commercial business, newly for a diagnosed patients, GBM

We have critical infrastructure, established gained in support indications. to strength launches and future the financial essential new built knowledge,

is strong more many the patients TTFields with business that sustainable, GBM penetration patients from we but therapy. XXXX, net and In over XX% $X.X know to and that in benefit there generated year The our billion ranging X,XXX key XX% from revenue with can are rates active on in ended markets, GBM we therapy.

we and patients and such, care engagement caregivers. As focused providers, remain health of education on

umbrella decision-making bringing of streamline our renewing intention sales, marketing we with under to and medical the year, business. Last reorganized team, one growth CNS improve goal coordination with the and in leadership our GBM

TTFields treatment We TTFields equipped ensure benefits of and awareness and Optune on for the aware driving focused Optune want since appropriate experimental as new providers patients of approval fully to years among also in patients. GBM, situations. therapy. FDA are greater some Seven are see in of diagnosed We newly still a to advocate are

social providers To bolstered believe and new across a channels, patient-focused this and variety will a foundation pursuing the as our including in return years blueprint and awareness efforts marketing educational growth coming and to launches greater provide streamlined media of other traditional patients, end, provide We we the our to with commercial for media. as have our in structure, well commercial are efforts indications.

of XXXX patients data real standard XXXX, In bevy TTFields. real large evidence review treated central XX,XXX and GBM. Dr. as world world Cory the populations, Published registry when US the Duke evidence treatment a for of care physician brain working such change publications and saw of practice. of through are from Neff to included have paramount in we University's supporting of spanning shift the use studies XXXX, IQVIA data tumor and These

periods long the Prague, single study with analyzed Na in Homolce from GBM as patients such XX nonhomologous a at treated over have Others tracked which center, years. TTFields Hospital

Du therapeutic from We for studies key review by Xue average evidence have also seen world multiple the the related of and potential TTFields in that found Medical Sichuan that A growth was become of TTFields Oncology, has hotspot. North stated our real research College, Dr. to Asian Frontiers in rate studying publications markets. recent XX% a

of world to publications common in opus crucial the of drive our will studies evidence to validation contribute and, efforts The supporting these of our greater results has and many EF-XX be study. pivotal over the TTFields the clinical been The adoption. clinical to of cases, use theme improvement real the

would pivotal of I today to like line the with positive LUNAR results study. our close from discussion top a

first with with cancer to platinum-based checkpoint the LUNAR including line a cell chemotherapy. docetaxel reminder, Stage designed the regimen or immune either evaluate inhibitors As together TTFields use for a lung of of progression non-small treatment was following X

in a announced together its In TTFields demonstrating survival for treated significant patients met with and extension statistically overall primary standard LUNAR endpoint, clinically with therapies. we meaningful January,

treated inhibitors docetaxel inhibitors statistically alone. a versus we overall TTFields checkpoint overall extension patients significant immune a and for immune treated with and TTFields trend patients in and Further, meaningful checkpoint with docetaxel saw and in survival versus alone for positive clinically survival

do X a crucial data year, believe patients world. with XX,XXX thousands We second the around cell the as cancer. lung non-small the In Stage seek more treatment US, patients lung diagnosed cancer these line represent cell for non-small finding each in

Since pembrolizumab was there LUNAR of transform for for the in XXXX, has paradigm patients, tumor believe extending more little potential generally solid progress setting the in data treatment We and in approved to to therapy. future these these has patients. the survival this the point been

patients forward Our team for with later publication, in and investors analyze data year. and sharing and data we preparation continues full the to to the physicians, a this presentation look

product that, to discuss it efforts. Asaf other clinical in now With will turn our I and development to updates

Asaf Danziger

It topline a key achievement to excitement study. Novocure. LUNAR is with readout pivotal Bill. I if is you, transform Bill's the Novocure first company. tumors we pivotal pivotal years, successful, first our expect echo completed of our LUNAR the outside treating the two studies, would and Thank four study read like out of to our for will coming also which which, immunotherapies brain. first of in solid the is about positive study the

at more I began I never XXXX, and I Novocure career ago, can have or that XX years my felt attest than excited. engaged in more

what us. hard, Our and employees have worked I'm so awaits eager so for

readout. launches same in we time the thereafter, announce expect ovarian Early medical in METIS full we from pivotal cancer. PANOVA-X the expect to be line And In will study. commercial upcoming we and line results congress, at and the anticipate and present dataset. next study an we release top the XXXX cancer cell top year, more anticipate non-small to at about the Novocure. time, cancer, ovarian full is to fall, top Lunar the line At Shortly and we of incredible beyond. summer in with INNOVATE-X This come to lung an data

I array would select launching not team's remiss next European our the in be markets. recent to mention achievement, generation

has can optimize to thinner, previous the material the intensity delivered versions. systemic increase to without a lighter increase delivered flexible toxicity. that the shown intensity patient's to bed increased without increase They the Our in arrays of tumor also can efficacy TTFields an delivered of more new Preclinical tumor are in scalp. potentially heat a therapy than and TTFields research

will to Sweden. the in future The We study use the inform additional in limited to are with Austria, preparing expand plans launch launch markets. the this to utilizing are patterns arrays. data release successful new gathered program we patient After

what long of TTFields enhancements are expect line product designed optimize the Our of therapy. a we arrays new to be to first

to work, all coming have we hard call the I colleagues my advantage in Ashley, to in have successful times many the your as years. handing Before will you like at occasion the of would thank positioned take the know opportunity Novocure to you to rise Through ourselves for XXXX. past. a immense I

review will over call now to our fourth financials. turn I Ashley the to quarter

Ashley Cordova

$XX GBM million Thank primed revenue years. for net you, finished $XXX from strong million cash In and net and the a financial Asaf. growth in coming the in in our year business generated Novocure XXXX, operations. in position

to entry. development new business research market us commercial fueling is product for durable invest preparation aggressively and Our enables new launches in and and

$XXX quarter fourth specifically, in revenue. the In generated we net million

pleased expected, as are begins Germany that, to recover. to revenue prior revenues average We are report level starting month the in EMEA to active our per to return patient as net

As be process out a reminder, we that multiple to gradual quarters plays expect to this a for come.

the from compared in Collection aged to claims prior lower fourth periods. were quarter

reported successful for fee prior million to beneficiaries from revenue previously service coverage. appeals in denied we the year, $XX Medicare full claims established the for For billed of

predict. of exhausted claims coverage, and time beneficiaries will pursue claims established to largely were collect. to We remaining and previously will impossible the take in cadence And to to from accessible actively these appeal which We claims XXXX. believe payments those collections were amount denied are for Medicare prior continue settled the but most outstanding

reflect per drivers times of per quarter, in active closely business, revenue To times month. from XX month on last we reiterate core patients expect revenues patient our the net net to GBM XXXX, therapy active

margin XX%, period the same with in Gross from line quarter margin fourth our for the last year. was

year-over-year. in expenses reflects build pre-commercial in to $XX an indications. million, intended XX% strong of ahead the potential future an a increase activities of increase This were quarter investment SG&A foundation

in access aggressively in coming the enter identify markets We are also resources and years. new to market investing

the and totaled quarter invested Research full million, in development million $XXX $XX year. for with expenses the

clinical explore plan new labels slate study additive opportunities to indications, studies near current potential with expand in continue the evaluate of to use and of care. our conclusion, the to we approved in TTFields standards to As indications, of pivotal novel investing effects

invest optimize patient's to to therapy development quality product Additionally, efforts in designed we aggressively our continue of life. and

and million the $XX $XX million. share adjusted Our was per EBITDA fourth net for or negative loss a was $X.XX quarter

and to enable December many catalysts treat full investments therapies. these and Cash many long-term the are we growth the in million applicability investments of multitude totaled to investing on We on future. patients XX, for horizon, short-term our Novocure and focused value opportunities believe of us a XXXX. the drive as With realize will of near-term more and $XXX capability

a debulking being Philadelphia close was to She city's began accustomed dream a to from firetrucks of like the by surgery Linda one diagnosed her battalion chased dreamed XXXX. at her today took paying of she visits. treatment. outside XXXX. that neighbors I'd to her radiation firefighter. she and session became female March dozen highlighting After was GBM Since grew and first chemotherapy users. chief Two turns child, Medicine, home. undergoing with Her of home and fellow of her and in driving Optune Penn firefighters Linda Long in our seeing parked treatment

Optune. Linda using also has her disease years In the since not almost diagnosis, two began progressed. Linda's

and Race out she she raise on she way. for goes the the and participated of finds city fellow in Linda in National jewelry along parks, makes Society's year, While using objects up stones $XX,XXX. Hope. other daily and firefighters picks Last helped Brain and TTFields, her Tumor walks

People why are aggressive in make we survival of daily we as here forms strive reminder the and the can Linda some are most impact extend cancer. to like of of a we

back it the questions. for to turn will I that, operator With

Operator

Instructions]. [Operator

comes line first Our with question from Sun Na JPMChase. of the

Na Sun

in calling I'm Fye. for Jessica

when think platinum patients? limit the are data do or were So, you expanded think who congratulations first see of actually LUNAR is on use who will to thinking checkpoint treated you the to the actually that – patients patients the one apply in with – on the their data progressed KOLs Specifically, they inhibitors also how in questions line? Optune of they we data about do presentation the will and the

general, more in question, Novocure? we for timing the think data top will line and Second what for how do about the ovarian set mean

William Doyle

question all, for you congratulations first ovarian. first turn the with your question second for to of about much start I'll Pritesh top line. Shah LUNAR talk I'll the then over to thank the But and very Maybe

release all energized. regulatory and Asaf bring the couldn't during As they're prepared heads And preparing excited the we of mentioned whether more required remarks, in then company down, the patients. the therapy sort of are and data, in group they're commercial or for to everyone the be to steps the in whether group that is the that

label. that designed to TTFields And the variety trial the with With non-small we planning profound as the failure. I checkpoint said, we cancers bring question, as already next are label. first combined after clinical patients to really of will does lines. you be platinum was point specific And expect data, inhibitors. your the a direction research variety And to, we of are patients trials say But to to future treat respect in in to cancer. a the think that allude the in of in that clinical we're And when cell lung combination

other and and would in It's patients. in very it non-small to one cell expect so a So is indication. the doctors of prescribe lines continue not explore TTFields cancer other done indication. trial to to combinations, and what can lung we we And all that call immunotherapies a large combination

talk With about bit you ovarian. little that, Pritesh, can a maybe

Pritesh Shah

about were to an cancer that study. line, enrolled heard QX patient remind we the study, follow which on prepared remarks, last in up ovarian a XX-month ongoing of timeframe. study. excited And our in the that's as was in top very INNOVATE-X expect you as everybody is the reminder, I'll there's summer the XXXX. announce Again, We

cancer we the their So, remain we the will data, with learn data. to we implications. community Once perspective the ovarian excited clinical get on from work to to have

this So, enthusiastic we the to very community. cancer ovarian about remain more helping on come And front.

Operator

Wittes the Our next line question Capital. Jason Loop comes of from with

Jason Wittes

top line the data. LUNAR on Congratulations

or when we of LUNAR an data? see ETA is expectation will there full an of, the First

William Doyle

medical in failure but When ability most release, in of of clinical this. we journal. the a quickly major as know future any to or aware the as conducts publish moving I a market with or are to implications, we other a know tier conference at we we a present you specific and the that don't company publish trial announce risks because top press data success

for reason this that's So, the gap.

We to are data constituencies. the the eager all to get

And submitting medical process an at we're for the and conference. the in presentation so, both of publication preparing abstract the upcoming

As can it you but you when soon later this let year. and as that's we'll expect exactly know where, accepted,

Jason Wittes

that? in Has from enrollment any you've LUNAR terms trials from reaction in the field field terms the post even general curious there in announcement been of of I'd or be heard to reaction? users just what GBM on know

William Doyle

inhibitor of cancer It's group the hasn't in been original any since ago. tremendously years progress exciting. trials Again, particular there lung this non-small checkpoint six patients immune cell

to So, cancer, notwithstanding made all we progress everything the been that read being stubborn, has this about in cohort. multiple difficult in another treat fronts

I So exciting. the applying I communities the we're a same to physics the region understand it's that is body. of think And think that different this

our reinforcing treat of to it of underlines so, sort Fields fight ability of all solid Treating the and tumors difficult Tumor And of mutually to efforts. is

Operator

Next of question line with Huang Fargo. comes in a Wells Lei

Lei Huang

dialing Biegelsen. Lei It's in for Larry

in study talk Just a that Can were arms about line on the control balanced in characteristics and level first you therapy? your and active of terms please. the LUNAR, couple confidence patient

William Doyle

To as balanced sharing look arms study. that of groups forward we've the that the in expected And were said and this numbers. remind behaved the well control was terms we And control all randomized said, and I with details as a to in arms. the And the later press said, as appropriate we the expected balance. But it in say indications all just announced release summer. again, I'll show results in as you, I everyone, the

Lei Huang

LUNAR on In overall release, met you a endpoint today's survival. that press mentioned key secondary

confirmed docetaxel, the trend. arm. that missed a but study you hit IO So, that It was on positive on

on was mean IO that plus the against survival missed? TTFields of overall that terms that alone, endpoint So, in does endpoint docetaxel third

William Doyle

again, nothing the press what let in are new we just excited there's was me announced how think other I this. about And say than release. Again,

second a which checkpoint and hitting stated, total plus patients So or then, group. but inhibitors compared Treating alone was saw patients clinically we're with significant the TTFields immune statistically to in docetaxel a improvement treated compared to patients treated treated docetaxel. Treating had all plus we trend, to in inhibitors primary And the positive Tumor inhibitors treated all patients therapy immune you compared profound significant in that endpoint, statistical immune improvement – Fields and significance, Tumor we the and with endpoints, not secondary standard as plus the checkpoint combined, either Fields and with statistically meaningful line docetaxel in checkpoint with

Lei Huang

to Just not be having clear, specifically the you're on secondary to commenting overall third do endpoint with and survival.

You're like not commenting that, that or not? hit on whether

William Doyle

this year. That will later come

Lei Huang

Ashley, squeeze for can more I If please. in one

that If was in XXXX? expect you grow slightly understand was that And that some talk you $XX collection, may included if to in that be year, But we XXXX, from about fruit revenue of your can I do just last hanging if XXXX? tougher that you in down – revenue see So, revenue this do backlog your the a XXXX. just backlog directionally, growing year. million collection low you exclude

Ashley Cordova

reiterate Thanks in opportunity for the because important understand your message to the is it everybody question for extremely and modeling. this to

did the confirm in aged $XX that numbers. have Medicare you So from We we recorded right claims. million

So to these accessible remaining to exhausted actively continue prior and coverage were outstanding again, But we most and in collect. the are reiterate, are that the pursue collections you claims as largely were billed noted. that the appeal will US, these I that claims. started for will to just claims take patients time established And

remove in when So for would million we contribution consider you from $XX your baseline recommend forward-looking look you not XXXX aged to the model that claims at

should closely active patient business, month drivers net we times net months patient per as active the look are reflect core therapy. then, revenue per times growth revenue And GBM more which where forward our on of

we as look forward. growth growth So should revenue active patient drive

Operator

the Sandler. Jason Our with next Piper question of comes Bednar line from

Jason Bednar

of question some know maybe I Phase up on all see look, on this order, and METIS. In think gone on progress But, closing future in of your recent potentially days, stage are today. sufficient has Phase Fields programs. formally [indiscernible] none backfilling studies, trial, plus a in matter studies trials of the you're here enrollment them. to short pipeline? Has X chemo to and Treating later to adding just just cancer a from are the waiting how a the the way experience about process for few And the approach follow-up these planning patient the pipeline. Fields? How thinking Treating you still in yet gastric here Tumor recently. HEPANOVA, all X of with Great and here LUNAR few Tumor to then we've four that a to at what's But about recent enrolling changed right from

Asaf Danziger

Our use TTFields in future with our And some combine care. original – of trials trial to was drugs. to basically, is comparing we standard TTFields experimental

puts different have. regulatory what to So, in than we used this different a basically totally was which us area,

So experimental the indications higher, we are mention challenges X to I we are make additional trial. bit we is want and the more trials all and it are you excited the do regulatory that just within and to planning looking that Phase all that more. But And mentioned next and in challenging. a the for forward fact combining little and therapies two run

Jason Bednar

quick to within question. additional just expect Should Phase follow-up my start Xs Maybe calendar this add a other year? I before that on we

Asaf Danziger

Absolutely.

Jason Bednar

a When in in to But predicting for I helpful patient. bit that had do XXXX that We revenue. active was to here very back had around little to Germany modeling coming follow-up guidance. question, that's Maybe year, have revenue. revenue the XXXX. for in prior but This last is Lei's there don't think to forecast year, a to per different. we Ashley. think back advance affected one accurately situation just revenue using active I on want this that I question on Apologies patient lengthy we

per whole that's also past revenue But rising. communicated situation patient the claims. Medicare have You've you on Medicare

XXXX. I think X% to start here

day You then in recently have any expansion France think kicking should have offices Spain. Canada be international now. some opened that you I here in And and also with

wondering modeling that Street with could comment you for the with all mind, revenue of guess, this in year. on you're growth if I whether year-over-year just So, comfortable

Ashley Cordova

of hears make to sure is reiterate. Jason, a just right? claims, you're these that top message want critical remove they with is XXXX. opportunity the that again, need is appreciate very line I the That number of clean key do a so to base, impact the the that starting it in contributor that as to aged off everyone

when on you're But focusing to the then factors right point XXXX, you growth things. the in

our have US, to we as opportunity in active believe and diagnosed continue continued penetration markets the in Japan. access newly to large in there's more GBM like We patients markets Germany

have We geographical expansion.

revenue, building if some terms drive efforts in important we're XXXX, there, be other revenue. markets, at the to will because, of will doing but take of it France we primarily In looked that time material

in half focus revenue the would year the gain see of the I pattern. with and year collection this then this coming begin on to to online payer So beginning experience France of it as we back contribute towards

that about term And to and It then, recover. it recover. at course begin year short end should XXXX Germany talked to in kind gain. look arc pain the XXXX for this, that of the the that to expect recover, We've will but was of can through of over take you a long term

puts be impact growth think stable of going active those it's are And look Medicare. net at about expect the without to aged I the and then [ph] fundamental and revenue to the takes. core expectation driver, meeting for patient we when claims be So the

Jason Bednar

this grow year, Ashley? Germany Can

Ashley Cordova

activations, say, base Certainly. Yeah, Yes. recovery both, a a but also I price. in on would business

Operator

the Our Greg with from next question comes Fraser line Truist.

Greg Fraser

is to going. about is on I know maybe to think can it's I the how so was on far focus. comment how into how flex expansion launch wondering if the of the going launch array early Europe. could and rest But you comment you that

just Ashley. over would be for look you could about On appreciate the experience France comments uptake in in fair it as France, what like made, precedent back at But Germany to investors there a ramp think look the and time? that potential the

Asaf Danziger

The actually in decade so. flex every that every a was is I array Novocure. kind arrays looking It's not that of year something happened and new great or forward question This happen – question. is to the this

launch arrays see the Austria, that after the new pleased that. other countries waiting so we're to are it. launch. we results still are long think in and far, so very, are dozen going few proud of And and the very results. is about to our treating we with to term move far And very patients, we're We're I But something Sweden great.

will to So according say feel and that our comfortable. plans I it's we very

Ashley Cordova

Greg, I'll jump just in on France.

I at have not the to market. development active going at can think look you're a to look itself. actual We proxy patient

patients I So come you'll as payers. to we collection quarters for see expect start the look to would online. And cycle couple active active those then of a to see revenue patients recognized with to lag

the recommendation towards So And revenue in the actually my patient the back of you would the that results year. look be active the of and the use to see trajectory, that of once model half front at half growth experience the year.

Operator

from the ISI. comes with of question Vijay next line Our Evercore Kumar

Vijay Kumar

patients On known treatment the in that it's of we Do mutation [indiscernible] percentage the the LUNAR know arm, was or enrolled trial, control Bill, profile? PD-X I randomized, think trial? patients the the patients of in some for and you well mentioned status all And only balanced. it's

William Doyle

other you at answered the the to this about the conference. asked later cohorts and answers the Vijay, the Again, specifics the will be medical being asked just of year questions questions

Vijay Kumar

plan the study. on one Maybe more the for statistical

survival sample of XX% what's size I'm guess study? curious in to the think power end endpoints secondary of I powering the – the with I the overall this a study power point? was and power. the now the being detect is study happened original the

William Doyle

powering of study. change the the no was to there So

so, survival the in remains And in to and the two overall the primary study LUNAR powered secondaries. powered detect

Vijay Kumar

ex-CMS this to headwinds is in year-on-year? Ashley, up what one you ex-CMS, Revenues, – I if revenues are being for a CMS here. guiding XXXX? And fiscal understood, you

Ashley Cordova

recorded claims in aged we reminder, a as revenue in million Again, from XXXX. $XX

that that relates prior collected to So in we established on XXXX. Medicare patients cash to coverage that were billed

coverage. So establishment from to of prior this claims the aged

of We that claims. core the to onto And and balance recognize pursue but we'll to cash continue relate we business the it, appeal sheet as it does continue and not collect to today. those take

the look the of growth given forward recommendation growth active will the most our you Active revenue and model beyond, is our balance with patient as sheet, XXXX aged look we line that patient been revenue driver captured accessible fact be And so, to have as forward growth on growth. in the claims Medicare core

Vijay Kumar

XX through? million, half Ashley, flow what What maybe was XQ the I into that and In was that of did that think that how came – cadence? XQ?

Ashley Cordova

the line, to [indiscernible] top at Vijay, active that look and just of you you growth see attribute you aged you how year. patient can top see the that you cadence that When at acceleration, claim. revenue If the look growth on net can

Operator

question comes Emily line Wainwright. with Bodnar of H.C. from next Our the

Emily Bodnar

first soon, line ovarian may in was the you cell and with any from study non-small the if INNOVATE-X KEYNOTE-BXX a for overlapping? curious of and enrollment modeling I'm kind that launch discuss other? Maybe some Is reading when we timeframe? data that that having work out close a like Or can how those study on see do lung and of study? positive, maybe launch differ some to plans launch each from fairly cancer cancer update

William Doyle

to during that, the recall may two Novocure You really reorganized year, things. we accomplish

new separate and GBM and on to launch combine second and group the then activities. all to combine the Pritesh efforts the First, responsible focus all efforts of indications. that for business, our core and focus is

So, on Pritesh, maybe the comment in you required can multiple activities launch to indications.

Pritesh Shah

all, to among it opportunity multiple the therapy, to medical therapy. to us would awareness because generate because exciting would that populations TTFields the I our of oncology say from be us platform our therapy benefit of nature bring we of would allows patient it community. welcome for very First that can

having So works action separately. to of educate we're therapy our mechanism separately not on or the that way

out that parlay we'll be therapy And medical us the look happening to available, business look therapy. for and you and for franchise. LUNAR primarily sales of doing a from the approval, to same primarily of the do will in that will for indications. include the then build that to we the to what's the set to the first would market see preparation to and our planning, position of us community, tumor becomes doing benefit expect, fact how level promote our opportunity, foremost, to we're look finally the is that and as which our would a you oncology is, we a Given which understand we of context we're this as once allow really data, will transcend which pan launch the GBM will that, clinic, FDA would forward do the in the then And would and a we it'll commercial have implications work clinical getting organization, other into to data work in training,

good the lots we're will on journey we LUNAR. happening down come on started other things focus, into So, on opportunities. this double front. to And of indications this as And continue those with already

William Doyle

cell to respect that we'll we the everybody have trial cancer. going enrollment to first is no report line planned is KEYNOTE-BXX we're pilot in patient with there's case, that partnership on don't question Fields Tumor a It's we And as non-small It's numbers, report when undertaking in. a in Enrollment in and KEYNOTE-BXX, news. plus lung With the just has Merck, trial. combining Treating remind as really Keytruda been less always ongoing. ongoing your but

Operator

William the this to at remarks. any questions to like further no conference showing further I'm time. Doyle over And hand for And you. would I Thank back

William Doyle

many the to a prepared more patients treat exciting difficult tumors. of our just extremely Novocure. solid bringing working said We're to with on GBM couldn't more the to to threshold from this in what patients at other I'd like with that Asaf therapy echo many remarks be be time

this period. trials laying of out to year. and And exceptional absolutely updating We're strong XX execution read in year was forward come. next progress throughout set And it's really in foundation months, the XXXX at to our exciting a for on four the this we With transformational look pivotal you the consistent period to Novocure.

and just And last I'll XXXX, work for end, but firmly because also seems point XXXX Novocure at strange so you talking be so your their for echoing about thank also at Asaf, and efforts everybody this all we're forward. to And thanking far going almost into hard year. it

Operator

This you participating. concludes for Thank today's conference call.

may now You disconnect.

NovoCure Limited (NVCR) 23 Feb 232022 Q4 Earnings call transcript